STOCKS TELEGRAPH

Tag: Oramed

  • Oramed (ORMP) Stock Skyrockets Amid Joint Venture Development Plans

    Oramed (ORMP) Stock Skyrockets Amid Joint Venture Development Plans

    After Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) announced a strategic joint venture for the development and commercialization of its oral medication delivery technology, the company’s shares shot up the charts today. At $2.84 as of the most recent trading session, ORMP shares had risen 30.65%.

    OraTech Pharmaceuticals’ establishment

    A new company called OraTech Pharmaceuticals Inc. was founded in partnership with Hefei Tianhui Biotech Co., Ltd. (HTIT) after Oramed Pharmaceuticals signed final arrangements to construct it.

    The joint venture will concentrate on developing Oramed’s exclusive Protein Oral Delivery (POD) technology, including ORMD-0801, its leading oral insulin candidate. This project is in line with ORMP’s objective to transform the treatment of diabetes and increase the potential of oral biologics in the control of chronic illnesses.

    Strategic Investment and Equity Distribution

    Under the terms of the agreement, Oramed will transfer its POD technology and related pipeline assets to OraTech. Shareholders of ORMP will retain a majority equity interest in the new entity, allowing them to directly benefit from its future growth and commercialization efforts.

    To support development and production, Oramed and HTIT will collectively invest $75 million in capital, a portion of which will be allocated to a supply agreement ensuring efficient resource allocation.

    Enhancing Oral Medication Administration Methods

    To hasten the commercialization of oral insulin and other cutting-edge treatments, OraTech Pharmaceuticals will combine Oramed’s clinical development experience with HTIT’s sophisticated manufacturing capabilities.

    OraTech is well-positioned to restart a crucial Phase 3 clinical study for ORMD-0801 in the US thanks to a solid financial base and a highly skilled leadership team. OraTech wants to create a dependable and expandable supply chain by utilizing HTIT’s expertise in capsule production and economical manufacturing techniques.

    This strategic collaboration positions Oramed (ORMP) to not only redefine diabetes care but also unlock new possibilities for oral biologic treatments in chronic disease management.

  • Oramed Pharmaceuticals (ORMP): Shareholder Letter Spurs Bullish Trend

    Oramed Pharmaceuticals (ORMP): Shareholder Letter Spurs Bullish Trend

    After releasing a letter to shareholders, Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares has seen a significant increase on the US stock charts. As of the latest current-market check, ORMP stock price increased 18.82% to $2.66.

    Program For Stock Repurchases And Strategic Update

    Nadav Kidron, the CEO of Oramed Pharmaceuticals (ORMP), sent a detailed letter to the company’s stockholders. This letter is in response to Oramed’s recent announcement of its $20 million stock repurchase program, which was made in order to demonstrate the company’s belief in its inherent worth and future prospects. The letter gave stockholders a thorough rundown of the business’s latest operations and strategic advancements.

    Financial Milestones And Regulatory Engagements

    In the shareholder letter, Oramed detailed the repayment schedule from Scilex Holding Company for its Senior Secured Note, which commenced on December 21, 2023. Thus far, Oramed has received $40 million out of the total $102 million principal, with the next $20 million installment due in September.

    A major amount of the projected returns from this strategic investment is represented by this payback, and Oramed has been aggressively pursuing conversations with the U.S. Food and Drug Administration (FDA) about a new Phase 3 procedure.

    This refined protocol is strategically designed to target specific patient subgroups identified as significant responders through thorough analysis of both Phase 2 and Phase 3 data.

    Joint Venture And Future Prospects

    Oramed also announced the formation of a joint venture with its long-term partner, Hefei Tianhui Biotech Co., Ltd. (HTIT), centered around Oramed’s innovative oral drug delivery technology. The U.S.-based joint venture aims to develop, market, and commercialize products from Oramed’s oral insulin and Protein Oral Delivery (POD) pipeline, leveraging HTIT’s advanced manufacturing capabilities.

    The joint venture will be bolstered by a substantial capital infusion, with HTIT committing $70 million in cash and Oramed contributing $25 million in cash and stock. These funds are earmarked to support the successful completion of the Phase 3 trial in the U.S., alongside other critical clinical and business initiatives.

    Oramed and HTIT are also investigating ways to use HTIT’s production capacity and the upcoming introduction of oral insulin sales. Recent advancements and strategic initiatives by Oramed Pharmaceuticals demonstrate the company’s dedication to improving its cutting-edge therapies and increasing shareholder value.